SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-155179
Filing Date
2024-06-05
Accepted
2024-06-05 16:50:00
Documents
13
Period of Report
2024-06-05
Items
Item 5.07: Submission of Matters to a Vote of Security Holders

Document Format Files

Seq Description Document Type Size
1 8-K d816010d8k.htm   iXBRL 8-K 32250
  Complete submission text file 0001193125-24-155179.txt   150428

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA apls-20240605.xsd EX-101.SCH 2850
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE apls-20240605_lab.xml EX-101.LAB 17235
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE apls-20240605_pre.xml EX-101.PRE 10812
16 EXTRACTED XBRL INSTANCE DOCUMENT d816010d8k_htm.xml XML 3475
Mailing Address 100 FIFTH AVENUE WALTHAM MA 02451
Business Address 100 FIFTH AVENUE WALTHAM MA 02451 617-977-5700
Apellis Pharmaceuticals, Inc. (Filer) CIK: 0001492422 (see all company filings)

IRS No.: 271537290 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38276 | Film No.: 241022653
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)